the aid library

Filter

742

Environmental Determinants of Cardiovascular Disease

Bhatnagar, A. Circulation Research (2018) CC

Many features of the environment have been found to exert an important influence on cardiovascular disease (CVD) risk, progression, and severity. Changes in the environment due to migration to different geographic locations, modifications in lifestyle choices, and shifts in social policies and cultu ... more

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

The Pediatric Clinical Manual

Elaine Abrams, Wafaa El-Sadr, and Miriam Rabkin The International Center for AIDS Programm (2004)

Epidemic meningitis surveillance in the African meningitis belt

World Health Organization WHO (2014) C_WHO

This document is intended to serve as a reference for national public health policy-makers. It outlines the scope of potential meningitis surveillance strategies that make it possible to obtain the data required for epidemic detection, monitoring of epidemiological and microbiological trends, evalua ... more

WHO recommendations for prevention and treatment of maternal peripartum infections

World Health Organization WHO (2015) C_WHO

WHO technical consultation on oxygen access scale-up for COVID-19

World Health Organization WHO (2021) C_WHO

Field Manual PAHO/WHO Regional Disaster Response Team

Pan American Health Organization PAHOWHO (2010)

Handbook for Coordinating Gender-based Violence Interventions in Emergencies 2019
recommended

Protection Cluster (2019) C2

This handbook is a quick-reference tool that provides practical, field-level guidance to establish and maintain a GBV sub-cluster in a humanitarian emergency. It provides the foundations for coordination. More in-depth information can be pursued through resources referenced in this handbook. The GBV ... more

DHR-ICMR GUIDELINES FOR DIAGNOSIS AND MANAGEMENT OF RICKETTSIAL DISEASES IN INDIA

Indian Council of Medical Research (ICMR) (2015) C1

The present DHR-ICMR guidelines comprehensively address the various concerns regarding the clinical assessment, treatment, and laboratory diagnosis of rickettsial diseases in India and the world. It is hoped that physicians, health care workers, the scientific community, the regulatory agencies, pub ... more

Hospital Readiness Checklist for COVID-19

World Health Organization (Europe) (2020) C_WHO

Interim Version 24, February 2020 This checklist has been prepared with the aim of supporting hospital managers and emergency planners in achieving the above by defining and initiating actions needed to ensure a rapid response to the COVID-19 outbreak. The checklist is structured on eleven key co ... more

National palliative care training curriculum for HIV&AIDS, Cancer and other life threatening illnesses

Ministry of Health, Kenya (2013) CC

Centering communities in pandemic preparedness and response

The Independent Panel (2021) CC

Background paper 10 The Independent Panel for Pandemic Preparedness and Response May 2021

INDEX-TB GUIDELINES: Evidence Summaries and Guideline Panel Decision Tables Core Group Guideline Meeting

(2016) C1

This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from this meeting

Humanitarian Standards Pocket Guide

The Sphere Project; World Vision Singapore (2006)

Lista de medicamentos esenciales para el manejo de pacientes que ingresan a unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID 19. Tercera versión, 1 de febrero del 2022
recommended

Organización Mundial de la Salud OMS OPS (2022) C_WHO

List of essential medicines for the management of patients admitted in intensive care units with a suspected or confirmed diagnosis of COVID 19. Third version, 1 February 2022

Corticosteroids for COVID-19

World Health Organization WHO (2020) C_WHO

WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ... more

India: Leprosy Training Manual For Health Workers and Supervisors

National Leprosy Eradication Programme; National Health Mission; Ministry of Health & Social Welfare India (2014) C1

Course contents: What is Leprosy? Leprosy is a disease caused by a micro-organism called Mycobacterium leprae

Humanitarian Supply Management And Logistics In The Health Sector
recommended

Pan American Health Organization (2001)

Polio Laboratory Manual

World Health Organization (2004) C_WHO